[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563805":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":18,"responsibleParty":38,"collaborators":42,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":73,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":18},{"fullName":5,"class":6},"International Peace Maternity and Child Health Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LNG-IUS group","EXPERIMENTAL","Participants will receive Mirena placement after hysteroscopic polypectomy",[13],"Drug: Levonorgestrel Intrauterine System (LNG-IUS)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Participants will receive none additional treatment after hysteroscopic polypectomy.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Levonorgestrel Intrauterine System (LNG-IUS)","Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy",[9],[26],{"name":27,"affiliation":5,"role":28},"Jian Zhang","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","86+18017316017","zhangjian_sjtu@126.com",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Li Yan","86+18112137720","yanli7720@163.com",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Zhang Jian","Principal Investigator",[43,45,47,49],{"name":44,"class":6},"Nanjing Maternity and Child Health Care Hospital",{"name":46,"class":6},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"name":48,"class":6},"Shanghai First Maternal and Infant Health Hospital affiliated to Tongji University Medical School",{"name":50,"class":6},"RenJi Hospital","100563805","the-effect-of-levonorgestrel-intrauterine-system-in-preventing-endometrial-polyps-recurrence-100563805",false,"NCT06620939","The Effect of Levonorgestrel Intrauterine System in Preventing Endometrial Polyps Recurrence","The Effect of Levonorgestrel Intrauterine System in Preventing Endometrial Polyps Recurrence After Hysteroscopic Polypectomy: Protocol of a Multi-center Randomised Controlled Trial","Inclusion Criteria:\n\n1. （1）Women age 20 to 48 years old;\n2. （2）Previous history of endometrial polypectomy;\n3. （3）Postoperative pathology confirmed endometrial polyps；\n4. （4）Women without fertility desire within 2 years；\n5. （5）Signed informed consent.\n\nExclusion Criteria:\n\n1. （1）Contraindications for a hysteroscopic polypectomy or LNG-IUS or not willing to receive this type surgery；\n2. （2）Women who have a positive pregnancy test；\n3. （3）A I and II type submucosal uterine leiomyoma, congenital uterine malformation, atypical endometrial polyps, a (suspected) malignancy, atypical endometrial cells, reproductive tract infections；\n4. （4）Postoperative pathology confirmed non-endometrial polyps；\n5. （5）Postoperative pathology confirmed endometrial proliferative diseases which need hormone drug therapy after surgery；\n6. （6）Treatment with hormonal three months before surgery；\n7. （7）The uterine cavity is more than 10 cm deep；\n8. （8）Women with severe diseases；\n9. （9）Women who were enrolled in another clinical study that could potentially impact the objectives of this study prior to their initial visit were excluded.\n10. （10）Unable to cooperate with the study procedures for various reasons, such as language comprehension difficulties, mental illness, inability to travel to the study center, or poor compliance.","FEMALE","20 Years","48 Years",{"count":62,"type":63},558,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to determine whether the LNG-IUS is more effective to that of expectant in preventing endometrial polyp recurrence after hysteroscopic polypectomy.\n\nResearchers will compare LNG-IUS to expectant management to see if LNG-IUS works to reduce the recurrence rate of endometrial polyps.\n\nParticipants will:\n\nReceive Mirena placement or not after hysteroscopic polypectomy； Be scheduled for a follow-up with TVCD to screen for endometrial polyps recurrence every 6 months.",[69],"Endometrial Polyp",[71,72],"Endometrial polyp","Levonorgestrel intrauterine system","NOT_YET_RECRUITING","2024-10-02",{"date":76,"type":77},"2024-10-04","ACTUAL",{"date":79,"type":63},"2024-12-01",{"date":81,"type":63},"2028-12-31",{"name":40,"class":6}]